AbbVie sees 2014 approval of hepatitis drugs, shares rise

(Reuters) – AbbVie Inc issued a cautious 2014 profit forecast, but said it expects U.S. approval this year for its potentially lucrative new all-oral treatment for hepatitis C, sending its shares up…

    

Leave a Reply

Your email address will not be published.